Breakthrough “one and done” treatments such as Novartis’ Zolgensma and bluebird bio’s Lentiglobin will contribute to a 12% compound annual growth rate (CAGR) for orphan drugs through to 2024, according to a report by Evaluate Pharma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,